Volume: 44 Issue: 1
Year: 2024, Page: 114-119, Doi: https://doi.org/10.51248/.v44i1.4156
Received: Dec. 9, 2023 Accepted: Feb. 1, 2024 Published: May 1, 2024
Introduction: Triple Negative Breast Cancer (TNBC) is a type of breast cancer that fails to express Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) in Immunohistochemical analysis. TNBC has a unique molecular profile, aggressive nature and lack of efficient targeted therapies. The aim of the study was to evaluate the expression of basal markers like Epidermal Growth Factor Receptor (EGFR) and Cytokeratin 5/6 (CK 5/6) and to correlate their expression with the clinico-pathological parameters, thus enabling the identification of the aggressive basal like phenotype of TNBC in resource-constrained settings.
Methodology: The study was conducted at a South Indian tertiary care centre for 2 years. Data such as age of presentation, tumour measurements, margins and necrosis, numbers, levels and sizes of lymph nodes were collected. Data on histological type and grade, in situ component, lymphovascular and perineural invasion, stromal reaction and lymph node status were recorded. Primary Immunohistochemical studies were performed for the markers ER, PR and HER2.Patients with negative expression for all the three markers were identified. IHC studies for EGFR and Cytokeratin 5/6(CK5/6) were done on tissue blocks and the expression of these two markers were equated with the clinico-pathological parameters.
Results: Among the 94 cases, 44 cases (46.8%) expressed CK5/6 and 46 (48.9%) expressed EGFR. A plausible association was noted between the expression of the two markers with age of the patient, tumour size, histological grade and tumour necrosis.
Conclusion: Combination of the time honoured gross and histopathological examinations along with the application of basal markers like CK 5/6 and EGFR, helps in identifying the basal-like phenotype with dismal clinical outcome among the triple-negative breast cancers in resource-constrained settings. An insight into such an aggressive tumour, provided by these markers may be critical in designing personalized treatment strategies for such patients.
Keywords: Breast cancer; triple-negative; CK5/6; EGFR.
1. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al., Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Mehrotra, R., Yadav, K. Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 2022;13(3):209-218.
3. Chopra, R. The Indian scene. J Clin Oncol.2001;19(18 Suppl):106S-111S.
4. Munjal, K., Ambaye, A., Evans, M.F., Mitchell, J., Nandedkar, S., Cooper, K. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev. 2009;10(5):773-778.
5. Kumar, V., Abbas, A., Aster, J. Robbins and Cotran pathologic basis of diseases. 10th ed. Amsterdam: Elsevier;2020.p.1046-1050.
6. Rakha, E., Reis-Filho, J.S. Basal-like breast carcinoma: From expression profiling to routine practice. Archives of Pathology and Laboratory Medicine.2009;133(6):860-868.
7. Elston, C.W., Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 2002;41(3A):151-152.
8. Tan, G.H., Taib, N.A., Choo, W.Y., Teo, S.H., Yip, C.H. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. 2009;10(3):395-398.
9. Chen, J.H., Agrawal, G., Feig, B., Baek, H.M., Carpenter, P.M., Mehta. R.S., et al., Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol. 2007;18(12):2042-2043.
10. Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H., Robertson, J.F., Ellis, I.O. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
11. Nassar, A., Sookhan, N., Santisteban, M., Bry-Ant, S.C., Boughey, J.C., Giorgadze, T., et al., Diagnostic utility of snail in metaplastic breast carcinoma. Diagnostic Pathology.2010; 26(5):76.
12. Ahmed, M.Y., Samia, M., Mostafa, S., Mohammed, M.A., Hebat Allah, A. Clinicopathological characteristics of triple-negative breast cancer. Med. J. Cairo Univ. 2015; 83(1):797-803.
13. Bhargava, R., Striebel, J., Beriwal, S., Flickinger, J.C., Onisko, A., Ahrendt, G., et al., Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2(5):444-455.
14. Lerma, E.,Peiro, G. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her-2-neu (basal-like breast carcinomas). Mod Pathol.2007;20: 1200-1207.
15. Livasy, C.A., Karaca, G., Nanda, R., Tretiakova, M.S., Olopade, O.I., Moore, D.T., et al., Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-271.
16. Billar, J.A., Duek, A.C., Stuky, C.C., Gray, R.J., Wasif, N., Nrthfelt, D.W., et al., Triple-negative breast cancers: Unique clinical presentations and outcomes. Ann. Surgical Oncology. 2010;3:384-390.
17. Chockalingam, C., Rao, L., Rao, S. Clinico-pathological characteristics of triple negative and non-triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India. Breast Cancer (Auckl). 2012;6:21-29.
18. Rao, C., Shetty, J., Prasad, KH. Immunohistochemical profile and morphology in triple – negative breast cancers. J Clin Diagn Res. 2013;7(7):1361-1365.
19. Thike, AA., Cheok, PY., Jara-Lazaro, AR., Tan, B., Tan, P., Tan, PH. Triple negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23(1):123-133.
20. Hashmi, AA., Edhi, MM., Naqvi, H., Faridi, N., Khurshid, A., Khan, M. Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagnostic Pathology. 2014;9(1):43.
M. Lauvanya, G. Bhuvana, K. Swaminathan, M. Subarathi. An insight into immunohistochemical profile of triple negative breast carcinoma in a tertiary care center. Biomedicine: 2024; 44(1): 114-119